NCT01801917View on ClinicalTrials.gov

Efficacy and Tolerability of BAF312 in Patients With Polymyositis

PHASE2TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 24, 2013

Primary Completion Date

August 5, 2016

Study Completion Date

August 5, 2016

Conditions
Polymyositis
Interventions
DRUG

Placebo

Matching placebo tablet for oral administration

DRUG

BAF312

BAF312 in 4 dosage strengths in tablet form: 0.25 mg, 0.5 mg, 1 mg, 2 mg for oral administration

Trial Locations (8)

1083

Novartis Investigative Site, Budapest

4032

Novartis Investigative Site, Debrecen

40447

Novartis Investigative Site, Taichung

40705

Novartis Investigative Site, Taichung

85013

Novartis Investigative Site, Phoenix

M5G 2C4

Novartis Investigative Site, Torono

128 50

Novartis Investigative Site, Prague

85-168

Novartis Investigative Site, Bydgoszcz

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY